JEDD D WOLCHOK, MD
Osteopathic Medicine at York Ave, New York, NY
License number
New York 201197
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
1275 York Ave, New York, NY 10021
Phone
(646) 227-3813
Personal information
See more information about JEDD D WOLCHOK at radaris.comName
Address
Phone
333 E 30Th St APT 17C, New York, NY 10016
1100 Clove Rd, Staten Island, NY 10301
333 30Th St, New York, NY 10016
333 30Th St, New York, NY 10016
38 Summit Dr, Yulan, NY 12792
Organization information
See more information about JEDD D WOLCHOK at bizstanding.comMemorial Sloan Kettering CNCR - Jedd D Wolchok MD
1275 York Ave, New York, NY 10065
Categories:
Internal Medicine Physicians & Surgeons, Oncology Physicians & Surgeons
Phone:
(212) 639-2000 (Phone)
Professional information
Dr. Jedd Wolchok, New York NY - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
1275 York Ave, New York 10065
(800) 525-2225 (Phone)
(800) 525-2225 (Phone)
Certifications:
Internal Medicine, 1997, Medical Oncology, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065
Education:
Medical School
New York University School Of Medicine
Graduated: 1994
Nyu Langone Medical Center
Meml Sloan-Kettering Canc Ctr
New York University School Of Medicine
Graduated: 1994
Nyu Langone Medical Center
Meml Sloan-Kettering Canc Ctr
Jedd D Wolchok, New York NY
Specialties:
General Practice, Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Memorial Sloan-Kettering
1275 York Ave, New York, NY 10065
1275 York Ave, New York, NY 10065
Education:
New York University (1994), New York University (1997) *Internal Medicine, Memorial Sloan Kettering Cancer Center (2000) *Hematology
Compositions For Treatment Of Melanoma And Method Of Using Same
US Patent:
2002015, Oct 17, 2002
Filed:
Nov 27, 2001
Appl. No.:
09/996128
Inventors:
Alan Houghton - New York NY, US
Philip Bergman - Tarrytown NY, US
Jedd Wolchok - New York NY, US
Philip Bergman - Tarrytown NY, US
Jedd Wolchok - New York NY, US
International Classification:
A61K039/00, C12N009/64
US Classification:
424/185100, 435/226000
Abstract:
Melanoma can be treated in a mammalian subject by administering to the subject an immunologically-effective amount of a xenogeneic melanoma-associated differentiation antigen. For example, genetic immunization with a plasmid containing a sequence encoding human gp75 has been shown to be effective in treatment of dogs with melanoma.
Method And Compositions For Stimulation Of An Immune Response To Cd20 Using A Xenogeneic Cd20 Antigen
US Patent:
8021666, Sep 20, 2011
Filed:
Oct 31, 2002
Appl. No.:
10/285874
Inventors:
Maria Lia Palomba - New York NY, US
Alan Houghton - New York NY, US
Jedd Wolchok - New York NY, US
David A. Scheinberg - New York NY, US
Wendy K. Roberts - New York NY, US
Alan Houghton - New York NY, US
Jedd Wolchok - New York NY, US
David A. Scheinberg - New York NY, US
Wendy K. Roberts - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C07K 14/705, C07K 14/435, A61K 39/00
US Classification:
4241851, 424450, 424 851
Abstract:
Tolerance of the immune system for endogenous CD20 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed CD20 antigen. For example, mouse CD20, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against CD20 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of lymphomas and leukemia expressing CD20.
Alphavirus Replicon Particles Expressing Trp2
US Patent:
2012012, May 24, 2012
Filed:
Apr 8, 2010
Appl. No.:
13/263369
Inventors:
Jedd D. Wolchok - New York NY, US
Francesca Avogadri - New York NY, US
Robert A. Olmsted - Chapel Hill NC, US
Maureen Maughan - Chapel Hill NC, US
Francesca Avogadri - New York NY, US
Robert A. Olmsted - Chapel Hill NC, US
Maureen Maughan - Chapel Hill NC, US
International Classification:
A61K 39/00, A61P 35/00, A61P 35/04, A61P 37/04
US Classification:
4241991
Abstract:
The immune response to melanoma cells and tumors can be induced or significantly increased by administering to a subject a pharmaceutical composition comprising alphavirus particles, especially Venezuelan equine encephalitis virus replicon particles, which express the melanoma antigen dopachrome tautomerase (DCT, TRP2) in cells of the subject, with the result of tumor regression and/or inhibition of metastasis of a melanoma subject, or a decreased risk of the occurrence or recurrence of melanoma and/or decreased severity of melanoma in a subject not suffering from melanoma at the time of administration. The pharmaceutical composition described herein can be used in conjunction with other therapeutic agents, it can be administered on more than one occasion and it can be combined with administrations of other compositions such as protein or other immunogenic compositions, and/or adjuvants, with beneficial effects to the human or animal subject to which it has been administered.